Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Complete title: ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
| ANHL12P1 |
| Rebecca Gardner, MD |
| II |
Look up trial at NIH
Research Study Description
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Crizotinib and methotrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether brentuximab vedotin and combination chemotherapy is more effective than crizotinib and combination chemotherapy in treating anaplastic large cell lymphoma.
Eligibility Criteria (must meet the following to participate in this
study)
** For Eligibility information, please click on the "Look up trial at NIH" link above. **
Other eligibility criteria may apply.
| ANHL12P1 |
| Advanced Therapeutics Study Line |
| 206/987-2553 |
|
Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Lymphoma, Non-Hodgkin (NHL); Immunoproliferative Disorders
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.